Michael A Weber

Summary

Country: USA

Publications

  1. ncbi request reprint Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial
    Henry R Black
    Rush Medical College of Rush University, Chicago, IL 60612, USA
    JAMA 289:2073-82. 2003
  2. ncbi request reprint Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial
    Thomas D Giles
    LSU School of Medicine, New Orleans, Louisiana, USA
    Am J Hypertens 16:460-6. 2003
  3. ncbi request reprint ALLHAT--all hit or all miss? Key questions still remain
    Franz H Messerli
    Am J Cardiol 92:280-1. 2003
  4. ncbi request reprint Creating a combination antihypertensive regimen: what does the research show?
    Michael A Weber
    State University of New York, Downstate College of Medicine, Brooklyn, NY, USA
    J Clin Hypertens (Greenwich) 5:12-20. 2003
  5. ncbi request reprint Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center, University of Oklahoma, 5850 W Wilshire Boulevard, Oklahoma City, OK 73132, USA
    Am J Hypertens 17:252-9. 2004
  6. ncbi request reprint The role of the new beta-blockers in treating cardiovascular disease
    Michael A Weber
    Department of Medicine, State University of New York, Brooklyn, New York, USA
    Am J Hypertens 18:169S-176S. 2005
  7. ncbi request reprint Angiotensin II receptor blockers and cardiovascular outcomes: the evidence now and in the future
    M Weber
    Suite 4002, 350 Fifth Avenue, Brooklyn, New York, NY, 10118, USA
    J Renin Angiotensin Aldosterone Syst 2:S12-6. 2001
  8. doi request reprint Renal outcomes in hypertensive Black patients at high cardiovascular risk
    Matthew R Weir
    Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Kidney Int 81:568-76. 2012
  9. doi request reprint Systolic blood pressure and cardiovascular outcomes during treatment of hypertension
    Michael A Weber
    SUNY Downstate College of Medicine, Brooklyn, NY 11203, USA
    Am J Med 126:501-8. 2013
  10. doi request reprint Cardiovascular events during differing hypertension therapies in patients with diabetes
    Michael A Weber
    Department of Medicine, SUNY Downstate College of Medicine, Brooklyn, New York 11203, USA
    J Am Coll Cardiol 56:77-85. 2010

Collaborators

Detail Information

Publications81

  1. ncbi request reprint Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial
    Henry R Black
    Rush Medical College of Rush University, Chicago, IL 60612, USA
    JAMA 289:2073-82. 2003
    ..Hypertensive patients are often given a calcium antagonist to reduce cardiovascular disease risk, but the benefit compared with other drug classes is controversial...
  2. ncbi request reprint Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial
    Thomas D Giles
    LSU School of Medicine, New Orleans, Louisiana, USA
    Am J Hypertens 16:460-6. 2003
    ....
  3. ncbi request reprint ALLHAT--all hit or all miss? Key questions still remain
    Franz H Messerli
    Am J Cardiol 92:280-1. 2003
  4. ncbi request reprint Creating a combination antihypertensive regimen: what does the research show?
    Michael A Weber
    State University of New York, Downstate College of Medicine, Brooklyn, NY, USA
    J Clin Hypertens (Greenwich) 5:12-20. 2003
    ....
  5. ncbi request reprint Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center, University of Oklahoma, 5850 W Wilshire Boulevard, Oklahoma City, OK 73132, USA
    Am J Hypertens 17:252-9. 2004
    ..The purpose of this study was to assess the efficacy and safety of the angiotensin II receptor blocker olmesartan medoxomil in combination with hydrochlorothiazide (HCTZ)...
  6. ncbi request reprint The role of the new beta-blockers in treating cardiovascular disease
    Michael A Weber
    Department of Medicine, State University of New York, Brooklyn, New York, USA
    Am J Hypertens 18:169S-176S. 2005
    ..Nebivolol is currently available in Europe for the management of hypertension and is expected to be available soon in the United States...
  7. ncbi request reprint Angiotensin II receptor blockers and cardiovascular outcomes: the evidence now and in the future
    M Weber
    Suite 4002, 350 Fifth Avenue, Brooklyn, New York, NY, 10118, USA
    J Renin Angiotensin Aldosterone Syst 2:S12-6. 2001
    ..Given the excellent tolerability of the ARBs, it will be of value to examine the influence of ARBs on cardiovascular outcomes in all relevant patient groups...
  8. doi request reprint Renal outcomes in hypertensive Black patients at high cardiovascular risk
    Matthew R Weir
    Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Kidney Int 81:568-76. 2012
    ..Blacks have a modestly higher increased risk for more advanced increases in serum creatinine than non-Blacks...
  9. doi request reprint Systolic blood pressure and cardiovascular outcomes during treatment of hypertension
    Michael A Weber
    SUNY Downstate College of Medicine, Brooklyn, NY 11203, USA
    Am J Med 126:501-8. 2013
    ..This study was conducted to explore cardiovascular outcomes at differing on-treatment blood pressure levels...
  10. doi request reprint Cardiovascular events during differing hypertension therapies in patients with diabetes
    Michael A Weber
    Department of Medicine, SUNY Downstate College of Medicine, Brooklyn, New York 11203, USA
    J Am Coll Cardiol 56:77-85. 2010
    ..The aim of this study was to determine which combination therapy in patients with hypertension and diabetes most effectively decreases cardiovascular events...
  11. doi request reprint Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial
    George L Bakris
    Hypertensive Diseases Unit, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    Lancet 375:1173-81. 2010
    ..We assessed the effects of these drug combinations on progression of chronic kidney disease...
  12. doi request reprint Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy
    Michael A Weber
    State University of New York, Downstate College of Medicine, Brooklyn, NY 11203, USA
    J Hypertens 30:2213-22. 2012
    ..To determine whether blood pressure (BP) control in hypertensive patients achieved with combination drug therapy provides the same cardiovascular benefits as with single-agent therapy...
  13. doi request reprint Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial
    Michael A Weber
    State University of New York, Downstate College of Medicine, Brooklyn, NY 11203, USA
    Lancet 381:537-45. 2013
    ....
  14. ncbi request reprint An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurements
    Michael A Weber
    SUNY Downstate Medical School, Brooklyn, NY 11203, USA
    J Clin Hypertens (Greenwich) 8:241-50; quiz 251-2. 2006
    ..A treatment algorithm based on the angiotensin receptor blocker, telmisartan, was confirmed by the blinded end point of ABPM as an efficacious alternative to other antihypertensive regimens in clinical practice...
  15. doi request reprint A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial
    Michael A Weber
    State University of New York, Downstate College of Medicine, New York, NY 11203, USA
    Lancet 374:1423-31. 2009
    ..We investigated the blood-pressure-lowering effects of the new vasodilatory, selective endothelin type A antagonist, darusentan, in patients with treatment-resistant hypertension...
  16. doi request reprint ASH position paper: treatment of hypertension in patients with diabetes-an update
    George L Bakris
    Hypertensive Diseases and Diabetes Center, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    J Clin Hypertens (Greenwich) 10:707-13; discussion 714-5. 2008
    ..Last, an updated algorithm is provided that incorporates many of the new findings and is suggested as a starting point to achieve blood pressure goals...
  17. ncbi request reprint Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension
    Michael A Weber
    State University of New York Downstate College of Medicine, Brooklyn, NY, USA
    J Clin Hypertens (Greenwich) 8:840-9. 2006
    ..Adverse events, including clinical chemistry values, were similar in the drug-treated and placebo groups. Carvedilol CR has a clinically meaningful defined dose-dependent antihypertensive effect that persists throughout a 24-hour period...
  18. ncbi request reprint Beta-blockers in the treatment of hypertension: new data, new directions
    Michael A Weber
    State University of New York, Downstate Medical College, 450 Clarkson Avenue, Brooklyn, NY 11023, USA
    J Clin Hypertens (Greenwich) 10:234-8. 2008
  19. ncbi request reprint Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study
    Henry R Black
    New York University School of Medicine, New York, NY 10016, USA
    J Clin Hypertens (Greenwich) 9:760-9. 2007
    ....
  20. doi request reprint The foundation role of beta blockers across the cardiovascular disease spectrum: a year 2009 update
    Henry R Black
    New York University Medical Center, New York, NY, USA
    Am J Med 123:S2. 2010
    ..Their beneficial abilities include improvement of oxygen supply and demand (which can reduce myocardial ischemia), anti-arrhythmic properties, and beneficial effects on cardiac remodeling...
  21. ncbi request reprint Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker
    Michael A Weber
    State University of New York Downstate College of Medicine, Brooklyn, NY 11203, USA
    J Clin Hypertens (Greenwich) 5:322-9. 2003
    ..001 for each) with the increases in the GWBI scores. Controlling blood pressure appears to be an important element in improving subjective health perceptions of hypertensive patients...
  22. ncbi request reprint Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk
    Michael A Weber
    SUNY Downstate Medical College, 420 Lexington Avenue, Brooklyn, NY 10170, USA
    Blood Press 16:13-9. 2007
    ..It is noteworthy that the mean BMI of 31 in this cohort is clearly above the accepted diagnostic criterion of obesity and that 60% of patients are diabetic, possibly reflecting secular trends in clinical disease...
  23. ncbi request reprint Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?
    Michael A Weber
    State University of New York Downstate Medical Center, Brooklyn, NY, USA
    Rev Cardiovasc Med 7:45-54. 2006
    ....
  24. ncbi request reprint Angiotensin II receptor blockers in older patients
    Michael A Weber
    State University of New York Downstate College of Medicine, Brooklyn, NY, USA
    Am J Geriatr Cardiol 13:197-205; quiz 206-7. 2004
    ....
  25. ncbi request reprint New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
    Michael A Weber
    State University of New York Downstate College of Medicine, New York, New York 10170, USA
    Am J Cardiol 100:45J-52J. 2007
    ....
  26. ncbi request reprint Hypertension treatment and implications of recent cardiovascular outcome trials
    Michael A Weber
    SUNY Downstate College of Medicine, New York, NY 10170, USA
    J Hypertens Suppl 24:S37-44. 2006
    ....
  27. ncbi request reprint The antihypertensive efficacy and safety of a chronotherapeutic formulation of propranolol in patients with hypertension
    Domenic A Sica
    Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
    J Clin Hypertens (Greenwich) 6:231-41. 2004
    ..Propranolol CR is an effective antihypertensive formulation that may reduce blood pressure during the morning period of maximum cardiovascular risk...
  28. ncbi request reprint Blood pressure effects of combined β-blocker and angiotensin-converting enzyme inhibitor therapy compared with the individual agents: a placebo-controlled study with nebivolol and lisinopril
    Michael A Weber
    State University of New York, Downstate College of Medicine Brooklyn, NY, USA
    J Clin Hypertens (Greenwich) 14:588-92. 2012
    ..4 (P<.0001 vs combination), 14.4 ± 14.1 (P=.0470), and 16.1 ± 17.2 (P=.0704). Adverse event rates were similar in all groups. This study demonstrated the potential antihypertensive benefits of combining nebivolol with a RAS blocker...
  29. ncbi request reprint Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial
    Michael A Weber
    State University of New York, Brooklyn, NY, USA
    Lancet 363:2049-51. 2004
    ....
  30. doi request reprint ASH Position Paper: Dietary approaches to lower blood pressure
    Lawrence J Appel
    Department of Medicine, Division of General Internal Medicine, Johns Hopkins University, Baltimore, MD 21205 2223, USA
    J Clin Hypertens (Greenwich) 11:358-68. 2009
    ..The current challenge is designing and implementing effective clinical and public health interventions that lead to sustained dietary changes among individuals and more broadly in the general population...
  31. ncbi request reprint First-step use of fixed-dose combination treatment in stage 2 hypertensive patients: has the time come?
    Michael A Weber
    SUNY Downstate College of Medicine, New York, New York, USA
    J Clin Hypertens (Greenwich) 9:276-84. 2007
  32. doi request reprint Telmisartan in high-risk cardiovascular patients
    Michael A Weber
    State University of New York Downstate College of Medicine, Brooklyn, New York, USA
    Am J Cardiol 105:36A-43A. 2010
    ..The choice of agent to be used in the long term could be based on other considerations, such as compliance and safety. Both cough and angioedema were higher with ramipril than telmisartan during the 56-month follow-up period in ONTARGET...
  33. ncbi request reprint Expanding the opportunities for blocking the renin-angiotensin system: introduction to a special supplement
    Michael A Weber
    State University of New York Downstate Medical Center, Brooklyn, NY, USA
    Rev Cardiovasc Med 8:S1-6. 2007
    ....
  34. ncbi request reprint ASH position paper: dietary approaches to lower blood pressure
    Lawrence J Appel
    Department of Medicine, Division of General Internal Medicine, Johns Hopkins University, Baltimore, Maryland, USA
    J Am Soc Hypertens 4:79-89. 2010
    ..The current challenge is designing and implementing effective clinical and public health interventions that lead to sustained dietary changes among individuals and more broadly in the general population...
  35. ncbi request reprint When and how to use self (home) and ambulatory blood pressure monitoring
    Thomas G Pickering
    Center for Behavioral Cardiovascular Health, Columbia Presbyterian Medical Center, New York, NY, USA
    J Am Soc Hypertens 4:56-61. 2010
    ....
  36. ncbi request reprint Clinical implications of aldosterone blockade
    Michael A Weber
    SUNY Health Science Center at Brooklyn, Brooklyn, NY 11203, USA
    Am Heart J 144:S12-8. 2002
    ..The significant risk reduction provided by the addition of spironolactone to standard therapy in patients with severe heart failure has renewed interest in aldosterone blockade...
  37. ncbi request reprint Circadian variations in cardiovascular disease: chronotherapeutic approaches to the management of hypertension
    Michael A Weber
    SUNY Downstate College of Medicine, Brooklyn, NY, USA
    Rev Cardiovasc Med 5:148-55. 2004
    ....
  38. ncbi request reprint The angiotensin II receptor blockers: opportunities across the spectrum of cardiovascular disease
    Michael A Weber
    SUNY Health Science Center at Brooklyn, Brooklyn, NY, USA
    Rev Cardiovasc Med 3:183-91. 2002
    ....
  39. ncbi request reprint A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly
    Michael A Weber
    Division of Endocrinology, Diabetes, and Hypertension, SUNY Downstate Medical Center, Box 1205, 450 Clarkson Avenue, Brooklyn, NY 11203 2098, USA
    Curr Hypertens Rep 5:319-21. 2003
  40. ncbi request reprint Angiotensin-II receptor blockers for hypertension and heart failure: quality of life and outcomes
    Michael A Weber
    State University of New York Downstate College of Medicine, Brooklyn, New York, USA
    Manag Care Interface 18:47-54. 2005
    ..Overall, angiotensin-II receptor blockers have a low incidence of side effects and provide improved QoL compared with standard therapies for patients with hypertension or heart failure...
  41. ncbi request reprint Evaluation of the 24 h effects of the angiotensin II receptor blockers: means to improve cardiovascular outcomes?
    Michael A Weber
    State University of New York, Health Sciences Center, New York, NY 10174, USA
    Blood Press Monit 8:215-22. 2003
    ....
  42. ncbi request reprint Controlled-release carvedilol in the treatment of essential hypertension
    Michael A Weber
    Department of Medicine, State University of New York Downstate College of Medicine, New York, New York 10170, USA
    Am J Cardiol 98:32L-38L. 2006
    ..We conclude that carvedilol CR is a very effective antihypertensive agent with clear dose-related peak blood pressure reduction and continuous 24-hour control...
  43. ncbi request reprint Introduction: the hemodynamic and vascular effects of angiotensin II: managing the consequences
    Michael A Weber
    State University of New York Health Science Center, Brooklyn 11203, USA
    Am J Hypertens 15:1S-2S. 2002
  44. ncbi request reprint Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?
    Michael A Weber
    State University of New York Downstate, College of Medicine, New York 10118, USA
    J Renin Angiotensin Aldosterone Syst 4:62-73. 2003
    ..Some studies are also investigating whether more extensive RAAS blockade using a combination of an ARB and an ACE-I will offer even greater protection than either agent alone...
  45. ncbi request reprint Treatment of elderly hypertensive patients with a delayed-release verapamil formulation in a community-based trial
    Michael A Weber
    State University of New York Downstate College of Medicine, Brooklyn, NY 11203, USA
    Am J Geriatr Cardiol 13:131-6. 2004
    ..CODAS verapamil was found to be efficacious and well tolerated among elderly hypertensive patients in this community trial...
  46. ncbi request reprint Calcium channel antagonists in the treatment of hypertension
    Michael A Weber
    SUNY Health Science Center at Brooklyn, Brooklyn, New York 11203 2098, USA
    Am J Cardiovasc Drugs 2:415-31. 2002
    ..Because of this important concept, calcium channel antagonists, like the other antihypertensive drug classes, are progressively being prescribed less often as monotherapy, but more typically as part of combination regimens...
  47. ncbi request reprint Managing the patient at risk for a second stroke
    Michael A Weber
    State University of New York Downstate College of Medicine, New York, USA
    J Hypertens Suppl 23:S41-7. 2005
    ....
  48. ncbi request reprint The ALLHAT report: a case of information and misinformation
    Michael A Weber
    State University of New York, Downstate College of Medicine, Brooklyn, NY 11203, USA
    J Clin Hypertens (Greenwich) 5:9-13. 2003
  49. ncbi request reprint Outcomes of treating hypertension in the elderly: a short commentary on current issues
    Michael A Weber
    Office of Scientific Affairs, SUNY Downstate College of Medicine, Brooklyn, NY 11203, USA
    Am J Geriatr Cardiol 12:14-8. 2003
    ..Even so, careful but effective control of blood pressure in elderly patients, including those over age 80, still remains a critical factor in preventing major cardiovascular events...
  50. doi request reprint Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension
    Michael A Weber
    aDownstate Medical Center, State University of New York, New York, New York bUniversity of Connecticut School of Medicine, Farmington, Connecticut cVirginia Commonwealth University Health System, Richmond, Virginia dUniversity of Chicago Medicine, Chicago eTakeda Global Development Center Americas fTakeda Pharmaceuticals International, Deerfield, Illinois
    Blood Press Monit 19:90-7. 2014
    ....
  51. doi request reprint Treatment of patients with hypertension and arthritis pain: new concepts
    Michael A Weber
    Downstate College of Medicine, State University of New York, Brooklyn, New York 10022, USA
    Am J Med 122:S16-22. 2009
    ..This article reviews some preliminary preclinical and clinical studies of key safety data of an investigational new NO-donating anti-inflammatory agent...
  52. ncbi request reprint The 24-hour blood pressure pattern: does it have implications for morbidity and mortality?
    Michael A Weber
    State University of New York Downstate Medical College, Brooklyn, New York, USA
    Am J Cardiol 89:27A-33A. 2002
    ..Inclusion of the telmisartan plus ramipril treatment arm will allow investigation of the potential advantages presented by combining an angiotensin-converting enzyme inhibitor with an angiotensin II receptor antagonist...
  53. doi request reprint Association of Clinical Researchers and Educators a statement on relationships between physicians and industry
    Michael A Weber
    State University of New York, Downstate College of Medicine, Brooklyn, New York, 112013, USA
    Endocr Pract 18:1029-37. 2012
    ....
  54. ncbi request reprint ONTARGET: questions asked, questions answered
    Michael A Weber
    J Clin Hypertens (Greenwich) 10:427-30. 2008
  55. doi request reprint Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial
    Sverre E Kjeldsen
    Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA
    Blood Press 17:170-7. 2008
    ..We conclude that valsartan compared with amlodipine reduces the risk of developing diabetes mellitus, particularly in hypertensive patients with the highest susceptibility for development of diabetes...
  56. ncbi request reprint Appropriate dose transition to a controlled-release formulation of carvedilol in patients with hypertension
    George L Bakris
    Hypertensive Diseases Unit, Section of Endocrinology, Diabetes, and Metabolism, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
    Rev Cardiovasc Med 9:96-105. 2008
    ..The use of carvedilol CR (once daily) may be preferable to a twice-daily regimen...
  57. ncbi request reprint Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT, USA
    Am Heart J 151:176-84. 2006
    ..Therefore, we used ambulatory blood pressure monitoring (ABPM), an automated and objective measure of blood pressure (BP) to overcome these shortcomings in a large community-based trial...
  58. ncbi request reprint Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension
    William B White
    Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, Conn 06030 3940, USA wwhite nso1 uchc edu
    Hypertension 41:1021-6. 2003
    ..Furthermore, eplerenone reduced microalbuminuria to a greater extent than amlodipine in this older patient group...
  59. ncbi request reprint Long-term cardiovascular consequences of diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors
    Franz H Messerli
    JAMA 289:2067-8; author reply 2069-70. 2003
  60. ncbi request reprint Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy
    William C Cushman
    University of Tennessee College of Medicine and Veterans Affairs Medical Center, Memphis, TN, USA
    Am J Geriatr Cardiol 17:27-36. 2008
    ..Irbesartan/HCTZ combination therapy allowed SBP goal attainment in 73% of patients aged 65 years or older whose hypertension was previously uncontrolled with antihypertensive monotherapy...
  61. ncbi request reprint The evolution of combination therapy in treating hypertension
    Michael A Weber
    J Clin Hypertens (Greenwich) 9:1-4. 2007
  62. ncbi request reprint Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass
    Joel M Neutel
    Orange County Heart Institute and Research Center, Orange, California, USA
    Am J Hypertens 17:37-42. 2004
    ..This study examined whether combined therapy has greater arterial and cardiac effects than doubled doses of the individual drugs...
  63. ncbi request reprint Efficacy of combination therapy with amlodipine besylate/benazepril hydrochloride for lowering systolic blood pressure in stage 2 hypertension
    Joel M Neutel
    Orange County Research Center, Tustin, CA 92780, USA
    Am J Geriatr Cardiol 15:142-50. 2006
    ..Adverse event rates were low and similar in all treatment groups. This study demonstrated that combination therapy is superior to monotherapy in older patients with stage 2 systolic hypertension and is well tolerated...
  64. pmc Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy
    Elizabeth O Ofili
    Clinical Research Center, Morehouse School of Medicine, Atlanta, GA 30310, USA
    J Natl Med Assoc 98:618-26. 2006
    ..In conclusion, irbesartan/HCTZ treatment provided SBP/DBP goal attainment in approximately two-thirds of Caucasian, African-American and Hispanic/Latino patients with SBP uncontrolled on antihypertensive monotherapy...
  65. ncbi request reprint Clinical experience with perindopril in elderly hypertensive patients: a subgroup analysis of a large community trial
    Joel M Neutel
    Orange County Research Center, Tustin, California 92780, USA
    Am J Cardiovasc Drugs 4:335-41. 2004
    ..To evaluate the effectiveness and safety of perindopril in a subgroup of 3010 elderly (> or =65 years) hypertensive patients, who participated in a large US general practice-based community trial...
  66. ncbi request reprint Feasibility of treating prehypertension with an angiotensin-receptor blocker
    Stevo Julius
    University of Michigan, Department of Internal Medicine, Division of Cardiovascular Medicine, Ann Arbor, MI 48106, USA
    N Engl J Med 354:1685-97. 2006
    ..Prehypertension is considered a precursor of stage 1 hypertension and a predictor of excessive cardiovascular risk. We investigated whether pharmacologic treatment of prehypertension prevents or postpones stage 1 hypertension...
  67. ncbi request reprint Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
    Deepak L Bhatt
    Cleveland Clinic, Cleveland, USA
    N Engl J Med 354:1706-17. 2006
    ..Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events...
  68. ncbi request reprint Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study
    Joel M Neutel
    Orange County Research Center, Tustin, CA 92780, USA
    J Clin Hypertens (Greenwich) 7:641-6; quiz 647-8. 2005
    ..This data supports the recommendation of the JNC 7 for the use of combination therapy in patients with stage 2 hypertension...
  69. ncbi request reprint A focus on heart failure and other age-related cardiovascular conditions
    Michael A Weber
    Am J Geriatr Cardiol 14:221-3. 2005
  70. ncbi request reprint Expanding the definition and classification of hypertension
    Thomas D Giles
    Louisiana State University School of Medicine, New Orleans, LA 70112, USA
    J Clin Hypertens (Greenwich) 7:505-12. 2005
    ..We believe it would be preferable to classify all individuals as either normal or hypertensive, based on their cardiovascular evaluation, using the four categories of normal and stages 1, 2, and 3 hypertension...
  71. ncbi request reprint Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients
    George L Bakris
    Department of Preventive Medicine, Rush University Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 7:587-95; quiz 596-7. 2005
    ..We conclude that an angiotensin receptor blocker as part of a BP-lowering strategy is effective in previously untreated African-American patients, although a higher proportion will require the use of a diuretic compared with Caucasians...
  72. ncbi request reprint Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial
    Sverre E Kjeldsen
    Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA
    J Hypertens 24:1405-12. 2006
    ..Type 2 diabetes is emerging as a major health problem, which tends to cluster with hypertension in individuals at high risk of cardiovascular disease...
  73. ncbi request reprint Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes
    James R Sowers
    University of Missouri Columbia and Harry S Truman VA Medical Center, 65212, USA
    J Clin Hypertens (Greenwich) 8:470-80. 2006
    ..Irbesartan/HCTZ fixed combinations achieved SBP goals in over half of the T2DM patients and nearly three quarters of patients with the metabolic syndrome, with SBP uncontrolled on antihypertensive monotherapy...
  74. ncbi request reprint A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension
    Robert J Weiss
    Androscoggin Cardiology Associates, Auburn, ME 04210, USA
    J Clin Hypertens (Greenwich) 9:667-76. 2007
    ..002). The overall adverse event experience was similar in the nebivolol (46.1%) and placebo (40.7%) groups (P=.273). Once-daily nebivolol is an effective antihypertensive in mild to moderate hypertensive patients...
  75. ncbi request reprint Drug choice affects treatment compliance and blood pressure outcomes in elderly hypertensive patients
    Michael A Weber
    Am J Geriatr Cardiol 16:277-8. 2007
  76. ncbi request reprint Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    J Hypertens 25:1473-9. 2007
    ..Reduced renal function is predictive of poor cardiovascular outcomes but the predictive value of different measures of renal function is uncertain...
  77. ncbi request reprint Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 49:1982-8. 2007
    ..The purpose of this study was to determine the possible benefit of dual antiplatelet therapy in patients with prior myocardial infarction (MI), ischemic stroke, or symptomatic peripheral arterial disease (PAD)...
  78. ncbi request reprint The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial
    Joel M Neutel
    Orange County Research Center, Tustin, CA 92780, USA
    J Clin Hypertens (Greenwich) 7:578-86. 2005
    ..Treatments were well tolerated. This irbesartan/HCTZ treatment regimen achieved SBP goals in more than 75% of patients uncontrolled on monotherapy...
  79. ncbi request reprint Hypertension, the metabolic syndrome, and the risk of developing diabetes: is it time to change the guidelines?
    Michael A Weber
    J Clin Hypertens (Greenwich) 6:425-7. 2004
  80. ncbi request reprint The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy
    Stevo Julius
    University of Michigan, Department of Internal Medicine, Division of Cardiovascular Medicine, 24 Frank Lloyd Wright Dr, PO Box 322, Lobby M, Ann Arbor, MI 48106, USA
    Hypertension 48:385-91. 2006
    ..Moreover, these findings support the feasibility of comparative prospective trials in lower-risk hypertensive patients...
  81. ncbi request reprint Is there more to life than blood pressure?
    Michael A Weber
    J Clin Hypertens (Greenwich) 7:149-51. 2005